Compare Recursion Pharmaceuticals Inc (RXRX) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $3.31 (market cap $1.81B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $60.44. The key difference: Vanguard Emerging Markets Stock Index Fund ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | VWO | |
|---|---|---|
Market Cap | $1.81B | — |
Sector | Health | — |
52-Week High | $6.79 | $61.24 |
52-Week Low | $2.84 | $51.20 |
Enterprise Value | $1.33B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.33, up 1.22% in the last session, with a bearish technical signal and RSI near overbought levels. The company reported a Q2 2026 earnings miss with revenue of $54M and a net loss of $519M, reflecting a net margin of -961.97%. Recent news highlights participation in investor conferences and a Genentech partnership advancement, but competitive pressures and slow revenue growth remain concerns.
Outlook is cautious due to persistent losses and high cash burn, though partnerships provide some validation. Risks include execution challenges in drug discovery and reliance on milestone payments. Analysts show a mixed stance with 40% buy ratings, but the stock faces headwinds from weak profitability and bearish technical trends.
VWO trades at $60.49, up 0.27% with a bullish technical signal from moving averages. The ETF shows strong institutional accumulation with multiple advisors increasing positions recently. Emerging markets are experiencing record capital inflows as investors diversify beyond US stocks, with VWO offering low-cost exposure to developing economies at a 0.06% expense ratio.
The outlook remains positive given institutional support and emerging market momentum, though risks include China's weighting impact and potential volatility. VWO's low expense ratio and 2.4% dividend yield provide competitive advantages over peers like EEM (0.69% fee) for emerging market exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
